Methods of inhibiting presbyopia
US9283237B2 · kind B2 · utility
0Cited by
21References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 9, 2014 |
| Grant date | Mar 15, 2016 |
| Priority date | — |
| Expiry date | May 9, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are methods of inhibiting or reversing the progression of presbyopia in an eye by administering a βL-crystallin electrostatic interaction inhibitor. Presbyopia is caused by aggregation of the soluble crystalline lens proteins called the crystallins, particularly βL-crystallin. It has been found that the aggregation of βL-crystallin is an electrostatic phenomenon and that electrostatic interaction inhibitors can be employed to prevent the formation of βL-crystallin aggregates as well as to deaggregate already formed aggregates.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.